Brief: Tonix Pharmaceuticals Announces In-Licensing Phase 2/3-Ready Monoclonal Antibody Designed For Seasonal Prevention Of Lyme Disease (Tnx-4800)
17/09/2025 14:15
Sept 17 (Reuters) - Tonix Pharmaceuticals Holding Corp TNXP.O: TONIX PHARMACEUTICALS ANNOUNCES IN-LICENSING PHASE 2/3-READY MONOCLONAL ANTIBODY DESIGNED FOR SEASONAL PREVENTION OF LYME DISEASE (TNX-4800) Source text: ID:nGNX9xnLsr Further company coverage: TNXP.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tonix Pharmaceuticals Holding
See all newsBrief: Tonix Pharmaceuticals Says Dr. Reddy's Files ANDA With Paragraph IV Patent Certification For Generic Tonmya
Brief: Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement For Tonmya®
Tonix Pharmaceuticals Holding Corp. reports results for the quarter ended June 30 - Earnings Summary
Tonix Q2 revenue rises sharply on TONMYA launch
Tonix Pharmaceuticals Holding Corp. expected to post a loss of $2.70 a share - Earnings Preview